Xconomy

DECEMBER 18, 2018

The venture investment, which the San Diego startup announced Tuesday, is one of only a few so-called mega-rounds—$100 million or more—recorded this year in the region. (In Thompson to its board of directors. In Southern California, rounds that large are more often raised by life sciences companies.)

Southern California 110

Southern California San Diego Software Invest 110

Xconomy

JANUARY 11, 2017

The firm acknowledged price hikes on several drugs that stayed—sometimes barely—under the 10 percent limit that CEO Brent Saunders pledged last September, in what he called a “ social contract with patients.” The first test of pharmaceutical giant Allergan’s promise to behave responsibly came last week.

Pricing 40

Pricing .Net Conference Invest 40

Xconomy

OCTOBER 26, 2018

In the biotech investment and research communities this week, much of the attention was turned to Europe.

Pricing 86

Pricing Conference Research Invest 86

Xconomy

JULY 14, 2017

Akcea Therapeutics is joining the parade of biotechs going public, but the company had to cut its stock price and sell more shares in order to pull it off. But the biotech priced its offering of 15.6 Cambridge, MA-based Akcea had planned on raising $125 million from the initial public offering, and it hit that target.

Pricing 57

Pricing Company Companies San Diego 57

Xconomy

APRIL 13, 2017

San Diego-based Tocagen (NASDAQ: TOCA ) priced its offering of 8.5 million shares priced between $10 to $12 each. Tocagen raised $85 million in its stock market debut today, and underwriters saw enough demand to increase the number of shares in the initial public offering. million shares at $10 per share.

San Diego 66

San Diego Pricing Demand Marketing 66

Xconomy

SEPTEMBER 6, 2019

Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something better. is counting on.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

NOVEMBER 20, 2019

Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. These are among the major findings of a survey of 500 industry leaders and investors conducted by investment bank Jefferies. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 78

Pricing Invest Develop Development 78

Xconomy

JANUARY 29, 2019

The New York-based startup said Tuesday that the new funding round, which is being led by Goldman Sachs Private Capital Investing group, brings its total investment to $35 million. Billie, a monthly subscription service for shaving and body care products for women, has raised $25 million.

Product 90

Product Services Invest Pricing 90

Xconomy

JULY 19, 2019

Soaring prices of Bitcoin and other so-called digital tokens were attracting investments from speculators hoping to get rich quick—but these virtual coin values were also known to drop just as suddenly, the US Treasury Department’s Financial Stability Oversight Council noted.

Pricing 89

Pricing Report Invest Venture Capital 89

Xconomy

MAY 9, 2019

Five biotechs priced their IPOs and at least one more is coming. According to IPO research firm Renaissance Capital , 47 IPOs have priced so far this year across all sectors, down 27 percent compared to the same period in 2018. Just as last year, healthcare IPOs lead the way.

Pricing 110

Pricing Research Capital Marketing 110

Xconomy

DECEMBER 14, 2018

Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used insulin. But the university also allowed them to patent the improvements they made, which enabled them to slap higher prices on each new version. to offer competitive pricing pressure.

Patents 77

Patents Pricing Competition San Diego 77

Xconomy

JUNE 3, 2019

Viking’s investment was a note that will convert into the company’s common stock after the initial public offering at a discount—equal to 90 percent of the price per share of the. Read more about the company’s history and its recent $40 million financing round hedge fund Viking Global Investors here.

Funding 79

Funding Pricing Invest Develop 79

Xconomy

DECEMBER 13, 2019

If you’re keeping track, FDA drug approvals have been on a tear in the past month with several decisions coming well ahead of their targeted dates. And then there’s Sarepta Therapeutics. Late Thursday, the FDA announced approval of the Cambridge, MA, biotech’s drug for Duchenne muscular dystrophy in patients who have a specific mutation.

Pricing 49

Pricing Southern California USC San Diego 49

Xconomy

JUNE 4, 2018

Inventory management is crucial to operating a successful retail operation. And as hard as it may be to believe, retailers “don’t really know what’s on the shelves,” says Sarjoun Skaff, founder and CTO of Bossa Nova Robotics.

Artificial Inteligence 69

Artificial Inteligence Pricing Product San Diego 69

Both Sides of the Table

JUNE 3, 2010

And the broader question of whether VC’s will continue to invest in the Twitter ecosystem. Discussion: Had a long chat about PicClick , a company founded by Ryan Sit in San Diego. Pricing engine helps publishers ascertain ad inventory pricing by analyzing ad transaction data from the market/exchanges. MetaMarkets.

Venture Capital 214

Venture Capital Startup Design S3 214

Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

AUGUST 30, 2016

Petco, the privately held pet supplies company based in San Diego, said today it led a $10 million Series A financing in Los Angeles-based Petnet, a three-year-old startup developing technology-enabled pet feeders and pet food delivery service. The deal also reflects Petco’s expanding interests in technology following the company’s $4.6-billion

San Diego 52

San Diego Los Angeles Mobile Equity 52

Xconomy

SEPTEMBER 13, 2016

MedCrypt, a healthtech cybersecurity startup founded near San Diego, has raised $750,000 in a seed financing round led by Safeguard Scientifics (NYSE: SFE ), a private equity fund in suburban Philadelphia that invests in healthcare, fintech, and digital media. Jude’s stock price.

San Diego 40

San Diego Startup Software Capital 40

Xconomy

MAY 2, 2019

Beyond Meat priced its IPO Wednesday evening at $25 per share, which was the high end of its revised range. million shares at that price. The food technology company’s upsized IPO has raised $241 million to finance plans to bring its plant-based “meat” to more grocery stores and restaurants across the country.

El Segundo 82

El Segundo Pricing Technology Venture Capital 82

Xconomy

MAY 1, 2019

Amazon’s stock price rose by 2.5 percent the day after it announced financial results and changes to the Prime program, while rivals Walmart (NYSE: WMT ) and Target (NYSE: TGT saw their stock prices. The Seattle e-commerce giant told analysts the move would cost around $800 million but that didn’t appear to concern investors.

Commerce 84

Commerce Pricing Startup Demand 84

Xconomy

MAY 17, 2019

During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. But such tools only work when companies play fair.

Pricing 79

Pricing Competition Tool Marketing 79

Xconomy

JULY 12, 2016

— 5D Robotics , founded in 2009 in Carlsbad, CA, (about 30 miles north of San Diego), has developed a device that integrates GPS, inertial guidance, optical positioning, and other technologies. SlantRange, a San Diego company founded almost three years ago, is a drone-related startup already generating sales.

San Diego 40

San Diego Seed Funding Guide Technology 40

Xconomy

APRIL 5, 2019

Perhaps it’s drug prices. Or maybe it’s regulation. While Gottlieb remained mindful of the FDA’s oversight role, he also tried to streamline the process for reviewing new drugs and medical devices. On numerous occasions, Gottlieb argued that generics would. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 69

Pricing San Diego Research Blogging 69

Xconomy

FEBRUARY 6, 2019

The South San Francisco, CA, biotech sold 9.25 million shares Wednesday evening priced at $19 apiece, which was the midpoint of its targeted $18 to $20 per share range. Those shares are expected to begin trading on the Nasdaq Thursday under the stock symbol “ALEC.”

Pricing 100

Pricing Develop Development San Diego 100

Xconomy

JULY 25, 2019

On Wednesday evening, Castle priced its offering of 4 million shares at $16 apiece, which was the high end of its targeted price range. Castle Biosciences is joining the public markets through a $64 million IPO that will support cancer tests that help doctors make treatment decisions. million shares in the range of $14 to $16 each.

Training 60

Training Pricing Activity Help 60

Xconomy

JANUARY 26, 2018

The United States has a new Health and Human Services chief who is expected to weigh in on the country’s drug-pricing debate. Xconomy examined its owners’ justification for the price, and why a drug-value watchdog pushed back hard.

Pricing 49

Pricing News Services San Diego 49

Xconomy

JULY 20, 2016

But the newer gene therapy delivery tools, or viral “vectors”—most commonly, adeno-associated viruses, or AAVs—have so far proved to be much safer than those used in the past, a key distinction since significant safety problems are what wasted away gene therapy investments at the turn of the century.

Pricing 40

Pricing Equity Marketing Tool 40

Xconomy

AUGUST 16, 2016

The industry can only go so far with growth through hyper-inflated pricing and mega-M&As. At some point pharma has to figure out how to make more drugs more efficiently, or face major dislocations like business-destroying price controls. The increasing need for new drugs is intense.

Product 40

Product Journal Venture Capital Demand 40

Xconomy

JULY 18, 2019

Here’s a recap of the biotech companies that priced IPOs Wednesday evening. Initial public offerings took a brief summer break the week of Independence Day, but healthcare IPO activity resumed this week as three more companies joined the US public markets.

Organization 77

Organization Pricing Activity Marketing 77

Xconomy

MAY 22, 2017

When Donald Trump heralded Ford’s announcement earlier this year that it would invest $1.2 Bloomberg reported that the cuts were a response to lagging stock prices and CEO Mark Fields’s desire to trim company costs this. Read more » Reprints | Share:

Report 55

Report Pricing Invest Artificial Inteligence 55

Xconomy

JUNE 11, 2018

Rockwell Automation is investing $1 billion in PTC, as the two companies team up to advance their vision of software-driven factories and industrial operations. As of this writing, it was trading at nearly $92 per share, up more than 5 percent from Friday’s closing price. Read more » Reprints | Share:

Yahoo 45

Yahoo Writing News Pricing 45

Xconomy

JUNE 22, 2018

Others that pushed their IPOs through couldn’t sell shares at the price they wanted. A total of 93 IPOs have priced as of Thursday, up 36.8 Seven biotech IPOs priced just this week. This year, the IPO window is wide open. percent compared to the same time last year, according to Renaissance Capital.

Pricing 49

Pricing Capital Draper San Diego 49

Xconomy

APRIL 6, 2018

There were plenty of policy and drug-price headlines, Read more » Reprints | Share: The FDA didn’t smile upon a big submission of depression studies from Alkermes, while those fighting liver disease got a mixed slate of data as a big medical conference looms.

Study 55

Study Pricing Conference Marketing 55

Xconomy

APRIL 20, 2018

The price of drugs is certainly on a lot of minds these days, including the mind of President Trump, as he reportedly will make a. While pembrolizumab notched the headline-grabbing data, others are also working to develop options for various subsets of patients. Who will be able to afford all these options?

Pricing 52

Pricing News Report Develop 52

Xconomy

JUNE 21, 2018

The San Francisco company priced its IPO late Tuesday, selling 6.25 The window for biotech IPOs remains wide open and six more companies have charged through it, raising more than $568 million in the span of 24 hours. The first was Eidos Therapeutics (NASDAQ: EIDX ), which raised $106 million in its stock market debut.

Study 72

Study Startup Pricing Funding 72

Xconomy

JULY 31, 2018

Co-founder Maria Markina says her New York-based startup gives women the convenience of a subscription service but at lower prices compared to other similar services. We’re not sacrificing quality, but we are bringing the price [down] so that many more women can afford” to purchase the subscription, Markina says.

Commerce 52

Commerce Pricing Organization Funding 52

Xconomy

OCTOBER 10, 2018

San Francisco-based Anaplan , one of five companies planning to close initial public offerings this week, raised the expected price range for its shares in an SEC filing Wednesday, signaling an IPO that could be richer than it had anticipated. If the shares price at $16—the midpoint of the new range—Anaplan.

Pricing 46

Pricing Software Venture Capital Company 46